What is BIA-ALCL?
BIA-ALCL (breast implant–associated anaplastic large cell lymphoma) is a rare cancer of the immune system — a T-cell lymphoma — that develops in the fluid or scar capsule around a breast implant; it is not a type of breast cancer.
Breast cancers start in the milk ducts or lobules of the breast. BIA-ALCL instead arises from T-lymphocytes, a type of white blood cell, in the tissue reaction surrounding an implant. In most patients it stays within the capsule, the layer of scar tissue that naturally forms around every implant.
The World Health Organization recognised BIA-ALCL as a distinct type of lymphoma in 2016. Regulators including the US Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Germany’s Federal Institute for Drugs and Medical Devices (BfArM) monitor reported cases and have issued guidance for patients and clinicians.
BIA-ALCL is rare and, when found early, usually curable with surgery. Most women with implants will never develop it, but everyone with implants should know the warning signs.
Which breast implants are linked to BIA-ALCL?
BIA-ALCL is strongly associated with textured breast implants; almost all cases with a known implant history have involved a textured implant at some point.
Textured implants have a rough surface designed to reduce movement and rotation; they include many anatomical (teardrop-shaped) implants used in reconstruction and some round implants. Smooth implants have a polished surface. The risk appears to be related to the surface texture rather than to whether the implant is filled with silicone or saline, or whether it was placed for cosmetic or reconstructive reasons.
The risk is not the same for all textured implants. Implants with a more heavily textured (macrotextured) surface have been linked with a higher risk. In 2019 one manufacturer’s macrotextured implants (Allergan Biocell) were recalled worldwide at the FDA’s request, and textured implants have been withdrawn or suspended in several European markets.
The exact cause is not fully understood, and researchers continue to study why only a very small minority of women with textured implants develop it. Current theories involve long-term inflammation around the textured surface, bacterial biofilm, and individual genetic susceptibility, acting together over many years.
- Even upper and lower pole
- Fuller lower pole
- Chest wall
How common is BIA-ALCL?
BIA-ALCL is rare: published estimates for women with textured implants range roughly from about 1 in 2,000 to about 1 in 86,000, depending on the implant type, country and study method.
These figures are uncertain for several reasons: the total number of women with implants is not precisely known, not every case is reported, and the disease can appear many years after surgery. The higher risk estimates generally relate to heavily textured implants. For women who have only ever had smooth implants, the risk appears to be extremely low.
Worldwide, over a thousand cases have been reported to regulators, and a small number of patients have died, mostly when the disease was diagnosed late or had spread beyond the capsule. National implant registers, including the UK’s Breast and Cosmetic Implant Registry and Germany’s national implant register (Implantateregister Deutschland), help track outcomes over time.
What are the symptoms of BIA-ALCL?
The most common sign of BIA-ALCL is a late swelling of the breast caused by a build-up of fluid (late seroma) around the implant, usually appearing years after surgery.
Signs to watch for include:
- Persistent swelling or enlargement of one breast, often painless, appearing a year or more after implant surgery — typically around 7 to 10 years.
- A lump in the breast or armpit.
- Pain, tightness or a change in the shape of the breast.
- Skin rash or redness over the breast, less commonly.
- Swollen lymph nodes in the armpit.
Most cases present as fluid alone; a smaller proportion present with a solid mass, which can indicate more advanced disease. Swelling in the first weeks after surgery is normal and different; a new swelling that appears long after you have healed should always be checked.
Many things other than BIA-ALCL can cause a late seroma, including injury, infection and implant rupture. But because the treatment is much simpler when BIA-ALCL is found early, late swelling should be investigated rather than ignored.
How is BIA-ALCL diagnosed?
BIA-ALCL is diagnosed by an ultrasound scan of the breast and, if there is fluid or a mass, by drawing off fluid or taking a biopsy and testing it in the laboratory for the marker CD30.
The usual steps are:
- Examination and ultrasound. Ultrasound is the first-choice test to look for fluid around the implant, a mass or enlarged lymph nodes. MRI may be used if ultrasound is unclear.
- Fluid sampling. If fluid is present, it is drained with a fine needle under ultrasound guidance. A good volume of fluid is sent to the laboratory, rather than being discarded.
- Laboratory tests. The fluid is examined under the microscope (cytology), and tested with immunohistochemistry and often flow cytometry. BIA-ALCL cells are typically CD30-positive and ALK-negative. A biopsy is taken if there is a solid mass.
- Staging. If BIA-ALCL is confirmed, a PET-CT scan is usually performed to check whether the disease has spread beyond the capsule.
Do not let fluid be drained and thrown away: if you have a late seroma, ask for it to be tested. A positive CD30 result alone is not enough for diagnosis, because CD30 can also appear in inflammation; the pathologist interprets all the findings together. Mammograms are not a reliable test for BIA-ALCL. For general advice about imaging with implants, see mammograms with breast implants.
In Germany, suspected cases are usually referred via the Frauenarzt (gynaecologist) to a certified breast centre (Brustzentrum); in Bulgaria, via the GP (общопрактикуващ лекар) to a mammology or oncology specialist. In the UK, the GP can refer you to a breast clinic.
How is BIA-ALCL treated?
The standard treatment for BIA-ALCL is surgery to remove the implant together with the entire surrounding capsule in one piece (total en bloc capsulectomy), which is usually curative when the disease is confined to the capsule.
Treatment follows international guidelines, such as those of the US National Comprehensive Cancer Network (NCCN), and is planned by a multidisciplinary team that includes a surgeon, a haematologist or oncologist and a pathologist.
- Total en bloc capsulectomy and implant removal. The implant, the complete capsule and any mass are removed, ideally without breaching the capsule, and sent to the laboratory. Any suspicious lymph nodes are removed.
- The other breast. Removal of the implant on the other side is commonly recommended, because cases in both breasts have occurred.
- Advanced disease. If the lymphoma has spread beyond the capsule, into lymph nodes or further, or cannot be fully removed, patients are referred to a haematology–oncology team. Treatment may include chemotherapy, targeted therapy with an anti-CD30 medicine (brentuximab vedotin) and sometimes radiotherapy.
Partial removal of the capsule is not recommended, because leaving capsule tissue behind increases the chance of the disease returning.
- Thickened capsule
- Implant inside its capsule
What is the outlook after BIA-ALCL treatment?
The outlook for BIA-ALCL confined to the capsule is generally very good, and most patients treated with complete surgery need no further cancer treatment.
Outcomes are less favourable when a mass is present or the disease has spread, which is why early recognition of late swelling matters. After treatment, patients are usually followed up with clinical examination and imaging for several years, as advised by their oncology team.
After recovery, many women want to restore the shape of the breast. Options include living without implants, a breast lift, fat grafting, or reconstruction with your own tissue. Most surgeons advise against placing new textured implants; smooth implants may be discussed in selected patients once the oncology team agrees.
Should I have my textured implants removed if I have no symptoms?
No — regulators including the FDA, MHRA and BfArM do not recommend removing textured implants in women without symptoms, because the risk of BIA-ALCL is low and removal surgery has its own risks.
Plastic surgery societies such as the American Society of Plastic Surgeons (ASPS) and the International Society of Aesthetic Plastic Surgery (ISAPS) share this view. Instead, women with textured implants are advised to:
- Know what type of implant they have.
- Be aware of the signs, especially late swelling or a lump.
- See a doctor promptly if symptoms appear.
- Continue routine breast screening and any implant follow-up recommended for them.
Some women choose removal or exchange because of anxiety, other implant problems or personal preference. That is a valid choice after discussing the benefits and risks with a surgeon. See breast implant removal and exchange.
What follow-up do women with textured implants need?
Women with textured implants and no symptoms do not need special tests for BIA-ALCL; they need awareness of the warning signs, routine breast screening for their age, and prompt assessment of any new swelling or lump.
In practice this means:
- Look and feel. Get to know how your breasts and implants normally look and feel, and notice changes in size, shape or firmness, particularly if one side becomes larger.
- Routine screening. Continue breast cancer screening as offered in your country. In Germany the Mammographie-Screening programme invites women aged 50 to 75 every two years; in the UK the NHS invites women from about 50 to 71 every three years; in Bulgaria screening and mammology checks are usually arranged through your GP. Tell the radiographer you have implants.
- Silicone implant checks. Separate from BIA-ALCL, silicone implants may rupture silently. The FDA suggests periodic ultrasound or MRI checks for silicone implants, beginning some years after surgery; your surgeon can advise on the right interval for you.
- Keep records. Keep your implant card and operation note safe, and register any change of address with your clinic if a recall or safety notice is issued.
Routine ultrasound purely to look for BIA-ALCL in women without symptoms is not generally recommended, because the condition is rare and almost always announces itself with swelling or a lump. If you notice a change, ask your doctor for an ultrasound and make sure any fluid drained is sent for testing rather than discarded.
How do I find out what type of breast implant I have?
The easiest way to find out your implant type is to check your implant card or patient passport, which lists the manufacturer, model, surface and serial number.
If you do not have it:
- Ask the clinic or hospital where you had surgery for your operation note and implant details.
- Ask your surgeon, or the surgeon’s current practice if they have moved.
- Check national registers: in the UK the Breast and Cosmetic Implant Registry, and in Germany the national implant register for operations recorded there.
- If records cannot be found, a surgeon may sometimes infer the type from imaging, but this is not always reliable.
Keep your implant card with your medical records and share the details with any doctor treating you, especially if you develop breast symptoms.
What is BIA-SCC and other capsule cancers?
BIA-SCC (breast implant–associated squamous cell carcinoma) is a very rare cancer that has been reported in the capsule around breast implants, separate from BIA-ALCL; it is far less understood and only a small number of cases have been described.
In 2022 the FDA issued a safety communication about reports of squamous cell carcinoma and various other lymphomas, including some B-cell lymphomas, in the capsule around breast implants. Unlike BIA-ALCL, cases have been reported with both smooth and textured implants. Symptoms reported have included swelling, pain, lumps or skin changes, often many years after surgery.
Because so few cases are known, the risk cannot be estimated reliably and the causes are not established. Regulators do not recommend removing implants because of BIA-SCC. The practical advice is the same: report any new swelling, lump or pain around an implant to your doctor, and ask for any capsule removed for unusual findings to be sent to the laboratory.
How a plastic surgeon can help
A plastic surgeon can help you understand your implant type and risk, check late swelling with appropriate imaging, perform total en bloc capsulectomy with your oncology team when indicated, and plan breast reshaping afterwards.
Dr. Fatih Kılıç is a plastic, reconstructive and aesthetic surgeon. Lymphoma diagnosis, staging and any further treatment are the responsibility of a haematology–oncology team; his role is surgical and reconstructive:
- Reviewing implant records, the implant card and ultrasound or MRI reports.
- Discussing whether symptoms need investigation, and coordinating fluid testing for CD30 where appropriate.
- Performing implant removal with total en bloc capsulectomy when indicated, with samples sent for pathology.
- Discussing removal or exchange of textured implants for women who choose it.
- Planning reshaping or revision after removal, and providing a written summary for your doctors at home.
If you are worried about textured implants, contact us to share your implant details for an opinion.
Getting an opinion on textured implants from abroad
Many women with implants placed years ago live in Germany or Bulgaria; Istanbul is about 1 hour 15 minutes by air from Sofia and about 3 hours from major German airports. If you have new swelling or a lump, have it assessed locally first by your own doctor, breast centre or breast clinic, because ultrasound and fluid testing should not be delayed. If you are worried about textured implants or want them removed or exchanged, you can share your implant card, scan reports and photographs online for an opinion from Dr. Fatih Kılıç. After any surgery you receive a written summary for your doctor at home. See international patients or contact us.
Frequently asked questions
What is BIA-ALCL?
BIA-ALCL is breast implant-associated anaplastic large cell lymphoma, a rare cancer of the immune system that develops in the fluid or scar capsule around a breast implant. It is a T-cell lymphoma, not a breast cancer, and is usually curable when found early.
Is BIA-ALCL a type of breast cancer?
No. Breast cancer starts in the breast ducts or lobules, whereas BIA-ALCL is a lymphoma that starts in immune cells within the capsule around an implant. It is diagnosed and treated differently from breast cancer.
Which implants cause BIA-ALCL?
BIA-ALCL is strongly associated with textured breast implants, particularly heavily textured surfaces. Almost all cases with a known implant history involved a textured implant. Both silicone and saline textured implants have been involved.
Can smooth implants cause BIA-ALCL?
Cases with a known history of only smooth implants are extremely rare, and the risk appears to be very low. Many patients with BIA-ALCL had a textured implant at some time, even if they later had smooth ones.
What is the risk of getting BIA-ALCL?
The risk is low. Published estimates for textured implants range roughly from about 1 in 2,000 to about 1 in 86,000, depending on implant type and the study. The risk with smooth implants appears to be much lower.
What are the first signs of BIA-ALCL?
The most common first sign is a persistent swelling of one breast caused by fluid around the implant, usually appearing years after surgery. Less often there is a lump in the breast or armpit, pain or a skin rash.
How long after implant surgery does BIA-ALCL appear?
BIA-ALCL usually appears many years after surgery, most often around 7 to 10 years, although it has been reported both earlier and much later. It is rare in the first year after surgery.
How is BIA-ALCL tested for?
An ultrasound looks for fluid or a mass around the implant. Fluid is drawn off with a needle and tested in the laboratory, where BIA-ALCL cells are typically CD30-positive and ALK-negative. A biopsy is taken if there is a solid lump.
How is BIA-ALCL treated?
Most patients are treated with removal of the implant and the entire surrounding capsule in one piece, called a total en bloc capsulectomy. This is usually curative when the disease is confined to the capsule. Advanced disease is treated by an oncology team and may include chemotherapy, targeted therapy or radiotherapy.
Should I have my textured implants removed as a precaution?
Regulators including the FDA, MHRA and BfArM do not recommend removing textured implants in women without symptoms. Instead, know your implant type, watch for swelling or lumps and see a doctor promptly if they appear. Some women choose removal after discussing risks and benefits with a surgeon.
What is BIA-SCC?
BIA-SCC is breast implant-associated squamous cell carcinoma, a very rare cancer reported in the capsule around implants. It has been seen with both smooth and textured implants. Very few cases are known, and routine implant removal is not recommended because of it.
How can I find out what implants I have?
Check your implant card or patient passport, which lists the manufacturer, model and surface. If you do not have it, ask the clinic or surgeon who performed your operation, or check whether your surgery was recorded in a national implant register.
Medically reviewed by Dr. Fatih Kılıç, Plastic, Reconstructive and Aesthetic Surgeon. This page is for general information and does not replace an individual consultation.